Ford Motor Company vs Eli Lilly And Co — how do they compare? Ford Motor Company trades at $12.26 (market cap $48.85B), while Eli Lilly And Co trades at $1,170 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 21.3× Ford Motor Company's market cap, and Ford Motor Company pays the higher dividend (4.9%). Which is the better fit depends on your goals — on Pluang, investors hold Ford Motor Company for 104 Days and Eli Lilly And Co for 93 Days on average.
| F | LLY | |
|---|---|---|
Market Cap | $48.85B | $1.04T |
Volume | 57,748,965 | 3,064,878 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $1.28K |
52-Week Low | $11.21 | $799.57 |
Typical Hold Time | 104 Days | 93 Days |
Enterprise Value | $180.81B | $1.09T |
Dividend Yield | 4.9% | 0.59% |
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.125, down 1.22% on the day, amid a challenging quarter with a 6.6% sales decline reported for Q3 2026 (Reuters, 2026-10-02). The stock shows a bearish technical signal, with moving averages indicating a downtrend. Fundamentally, the company reported a net loss of $8.18 billion for 2025, with negative profit margins and ROE, though operating cash flow remains strong at $21.28 billion. Recent news highlights supplier disruptions affecting F-150 production and a strategic shift toward hybrids.
The outlook for Ford is mixed, with analyst consensus leaning toward a 'Hold' (48.93% of ratings) and a price target of $15.90 suggesting potential upside. Key opportunities include the growing hybrid segment and strong commercial division, while risks involve ongoing sales volatility, high debt levels, and competitive pressures from Asian automakers. Investors should weigh the company's cash flow strength against profitability challenges and market share losses.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.
Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →